{"_buckets": {"deposit": "97a5c267-c922-4003-8785-fe77157480c3"}, "_deposit": {"created_by": 25, "id": "2001440", "owner": "25", "owners": [25], "owners_ext": {"displayname": "wataka", "username": "kuma1008"}, "pid": {"revision_id": 0, "type": "depid", "value": "2001440"}, "status": "published"}, "_oai": {"id": "oai:tsukuba.repo.nii.ac.jp:02001440", "sets": ["1789", "7829"]}, "author_link": ["573"], "item_5_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2019-09", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "9", "bibliographicPageStart": "1342", "bibliographicVolumeNumber": "11", "bibliographic_titles": [{"bibliographic_title": "Cancers", "bibliographic_titleLang": "en"}]}]}, "item_5_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "According to clinical trials, BRAF kinase inhibitors in combination with MEK kinase inhibitors are among the most promising chemotherapy regimens for the treatment of advanced BRAF-mutant melanoma, though the rate of BRAF mutation gene-bearing cutaneous melanoma is limited, especially in the Asian population. In addition, drug resistance sometimes abrogates the persistent efficacy of combined therapy with BRAF and MEK inhibitors. Therefore, recent pre-clinical study-based clinical trials have attempted to identify optimal drugs (e.g., immune checkpoint inhibitors or histone deacetylase (HDAC) inhibitors) that improve the anti-melanoma effects of BRAF and MEK inhibitors. In addition, the development of novel protocols to avoid resistance of BRAF inhibitors is another purpose of recent pre-clinical and early clinical trials. This review focuses on pre-clinical studies and early to phase III clinical trials to discuss the development of combined therapy based on BRAF inhibitors for BRAF-mutant advanced melanoma, as well as mechanisms of resistance to BRAF inhibitors.", "subitem_description_language": "en", "subitem_description_type": "Abstract"}]}, "item_5_publisher_27": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "MDPI", "subitem_publisher_language": "en"}]}, "item_5_relation_10": {"attribute_name": "PubMed番号", "attribute_value_mlt": [{"subitem_relation_type_id": {"subitem_relation_type_id_text": "31514399", "subitem_relation_type_select": "PMID"}}]}, "item_5_relation_11": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type": "isIdenticalTo", "subitem_relation_type_id": {"subitem_relation_type_id_text": "https://doi.org/10.3390/cancers11091342", "subitem_relation_type_select": "DOI"}}]}, "item_5_relation_9": {"attribute_name": "書誌レコードID", "attribute_value_mlt": [{"subitem_relation_type_id": {"subitem_relation_type_id_text": "10.3390/cancers11091342", "subitem_relation_type_select": "DOI"}}]}, "item_5_rights_12": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).", "subitem_rights_language": "en"}]}, "item_5_select_15": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_select_item": "publisher"}]}, "item_5_source_id_7": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "2072-6694", "subitem_source_identifier_type": "EISSN"}]}, "item_access_right": {"attribute_name": "アクセス権", "attribute_value_mlt": [{"subitem_access_right": "open access", "subitem_access_right_uri": "http://purl.org/coar/access_right/c_abf2"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Fujimura, Taku", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "藤澤, 康弘", "creatorNameLang": "ja"}, {"creatorName": "フジサワ, ヤスヒロ", "creatorNameLang": "ja-Kana"}, {"creatorName": "FUJISAWA, Yasuhiro", "creatorNameLang": "en"}], "familyNames": [{"familyName": "藤澤", "familyNameLang": "ja"}, {"familyName": "フジサワ", "familyNameLang": "ja-Kana"}, {"familyName": "FUJISAWA", "familyNameLang": "en"}], "givenNames": [{"givenName": "康弘", "givenNameLang": "ja"}, {"givenName": "ヤスヒロ", "givenNameLang": "ja-Kana"}, {"givenName": "Yasuhiro", "givenNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "573", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "70550193", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://nrid.nii.ac.jp/ja/nrid/1000070550193"}, {"nameIdentifier": "0000002388", "nameIdentifierScheme": "筑波大学研究者総覧", "nameIdentifierURI": "http://trios.tsukuba.ac.jp/researcher/0000002388"}]}, {"creatorNames": [{"creatorName": "Kambayashi, Yumi", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Aiba, Setsuya", "creatorNameLang": "en"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_access", "date": [{"dateType": "Available", "dateValue": "2021-09-28"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "Cancers_11-9.pdf", "filesize": [{"value": "548 KB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_0", "mimetype": "application/pdf", "size": 548000.0, "url": {"objectType": "fulltext", "url": "https://tsukuba.repo.nii.ac.jp/record/2001440/files/Cancers_11-9.pdf"}, "version_id": "87f292d9-4f67-4ac6-b45b-5be2294dbe7d"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Significance of BRAF Kinase Inhibitors for Melanoma Treatment: From Bench to Bedside", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Significance of BRAF Kinase Inhibitors for Melanoma Treatment: From Bench to Bedside", "subitem_title_language": "en"}]}, "item_type_id": "5", "owner": "25", "path": ["1789", "7829"], "permalink_uri": "http://hdl.handle.net/2241/0002001440", "pubdate": {"attribute_name": "PubDate", "attribute_value": "2021-09-28"}, "publish_date": "2021-09-28", "publish_status": "0", "recid": "2001440", "relation": {}, "relation_version_is_last": true, "title": ["Significance of BRAF Kinase Inhibitors for Melanoma Treatment: From Bench to Bedside"], "weko_shared_id": -1}
Significance of BRAF Kinase Inhibitors for Melanoma Treatment: From Bench to Bedside
http://hdl.handle.net/2241/0002001440
http://hdl.handle.net/2241/0002001440